Emergent Biosolutions Inc (EBS)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Emergent Biosolutions Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 66.7% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- 0.11 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.58 | – | 195 | -29.60 | -16.10 | -80 | -82 |
| 2025: Q1 | 1.19 | 588.30 | 222 | -26.00 | 30.60 | -11 | -15 |
| 2025: Q2 | -0.22 | – | 141 | -44.70 | -8.50 | 106 | 104 |
| 2025: Q3 | 0.91 | -56.10 | 231 | -21.30 | 22.20 | -2 | -6 |
| 2025: Q4 | -1.04 | – | 149 | -23.60 | -36.70 | 78 | 74 |
| 2026: Q1 | 0.12 | -89.90 | 156 | -29.70 | 4.40 | -34 | -36 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Emergent BioSolutions Inc., ein Life-Sciences-Unternehmen, bietet Lösungen zur Vorsorge und Reaktion auf versehentliche, vorsätzliche und natürlich auftretende Bedrohungen der öffentlichen Gesundheit in den USA, Kanada und international an.
| Employees | 900 |
|---|---|
| Headquarters | Gaithersburg, MD |
| Website | emergentbiosolutions.com |
| IPO Date | 15. Nov 2006 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Joseph C. Papa Jr., M.B.A., R.Ph. | CEO, President & Director | 1956 |
| Richard S. Lindahl M.B.A. | Executive VP & CFO | 1964 |
| Coleen Glessner | Executive Vice President of Quality, Ethics & Compliance | 1971 |
| Paul A. Williams | Senior Vice President of Products Business | 1967 |
| Simon C. Lowry M.D. | Chief Medical Officer and Head of Research & Development | 1973 |
| Jessica Perl | Senior VP, Corporate Secretary & General Counsel | 1981 |
| Michelle Pepin | Senior VP & Chief Human Resource Officer | – |
| Stephanie Duatschek | Chief Global Strategy & Franchise Development Officer | – |
| William Hartzel | Senior Vice President of Manufacturing & Bioservices | 1978 |
| Frank Vargo | VP & Treasurer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.